Do you want to read an article? Please log in or register.
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Leukemia
Related content
Lung, Respiratory and Thoracic Cancer
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study
Lung Cancer
Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S
doi: 10.1016/j.lungcan.2025.108422
Genitourinary Cancer
Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial
Ann Oncol
Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juárez V, Rini BI, Larkin J, Nolè F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ
doi: 10.1016/j.annonc.2024.12.008
Lung, Respiratory and Thoracic Cancer
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
J Thorac Oncol
Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS
doi: 10.1016/j.jtho.2025.05.019
Leukemia
Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group
Leuk Lymphoma
Zielonka K, Izdebski B, Drozd-Sokołowska J, Pruszczyk-Matusiak K, Puła B, Wiśniewski K, Sawicki W, Kalicińska E, Jabłonowska-Babij P, Butrym A, Buczek T, Subocz E, Hałka J, Witkowska M, Wilk M, Hryniewiecka M, Gruenpeter K, Cichocka E, Halicki P, Wdowiak K, Iskierka-Jażdżewska E, Kopińska A, Szlauer-Stefańska A, Szymczyk A, Wolska-Washer A, Kowalczyk J, Wróbel T, Hus I, Jamroziak K
doi: 10.1080/10428194.2025.2535693
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
RECOMMENDED
Gynecologic Cancer
First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
Petrelli F, Riboldi V, Bruschieri L, Villa A, Cribiu' FM, Borgonovo K, Ghilardi M, Ghidini A, Seghezzi S, Stefani A, Trevisan F
doi: 10.1016/j.ctrv.2025.102921
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
Lung, Respiratory and Thoracic Cancer
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Lancet Oncol
Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Yang H, Zhang X, Ma R, Li L, Liang L, Li M, Wang J, Wang Q, Wang B, Dai H, Shi Q, Yang J
doi: 10.1016/S1470-2045(25)00198-6
Leukemia
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL
Blood
Kater AP, Harrup RA, Kipps TJ, Eichhorst B, Owen C, Assouline SE, Lamanna N, Robak T Prof, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Langerak AW, Chyla B, Popovic R, Jiang Y, Millen R, Lefebure M, Thadani-Mulero M, Boyer M, Seymour JF
doi: 10.1182/blood.2024025525